M&A / Deals Biogen swoops on Apellis with $5.6bn offer PharmaphorumIn today's second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.M&A / DealsNephrologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum In today’s second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology. M&A / DealsNephrologyRead full story Post navigation Previous: Eli Lilly makes $7.8bn takeover play for CentessaNext: Novartis, Takeda Add Hundreds to Workforce Chopping Block Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
